Crescent Biopharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Crescent Biopharma Inc.
- Former names
- Glycomimetics Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Cayman Islands
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CBIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001253689
Board of directors
-
Alexandra Balcom · DirectorSince 2025
-
Daniel M. Junius · DirectorSince 2023
-
David Charles Lubner · DirectorSince 2025
-
Harout Semerjian · Director · Chief Executive OfficerSince 2023
-
Jonathan Violin · DirectorSince 2025
-
Joshua T. Brumm · Director · Chief Executive OfficerSince 2025
-
Mark Alan Goldberg · DirectorSince 2023
-
Patricia S. Andrews · DirectorSince 2023
- Since 2025
-
Rachel K. King · DirectorSince 2023
-
Scott Koenig · DirectorSince 2023
-
Scott Thomas Jackson · DirectorSince 2023
-
Susan Moran · DirectorSince 2025
-
Timothy R. Pearson · DirectorSince 2023
- Since 2025
Chief executives
Harout Semerjian
· Chief Executive Officer
Dates unknown
Joshua T. Brumm
· Chief Executive Officer
Since June 2025
Director election results
Annual meeting of June 5, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.7%
Board connections
13 of this board's directors also sit on 21 other boards.
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via David Charles Lubner and Joshua T. Brumm
- via Harout Semerjian and Patricia S. Andrews
- via Peter Evan Harwin and Tomas Kiselak
- via Scott Koenig and Scott Thomas Jackson
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via David Charles Lubner
- via Peter Evan Harwin
- via Peter Evan Harwin
- via Rachel K. King
- via Daniel M. Junius
- via Timothy R. Pearson
- via Rachel K. King
- via Patricia S. Andrews
- via Scott Thomas Jackson
- via Susan Moran
- via David Charles Lubner
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $30,612,625
- 2 purchases by 2 insiders
- Sold, last 12 months
- $1,511,627
- 16 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Joshua T. Brumm Director, Officer (Chief Executive Officer) | Open-market sale | −7,837 | $16.71 | $130,956 |
| Sep 18, 2026 | McNeill Jonathan Officer (President and COO) | Open-market sale | −3,839 | $16.71 | $64,150 |
| Sep 16, 2026 | Bispham Barbara Harlin Officer (See Remarks) | Open-market sale | −620 | $17.90 | $11,098 |
| Sep 16, 2026 | Joshua T. Brumm Director, Officer (Chief Executive Officer) | Open-market sale | −1,610 | $17.90 | $28,819 |
| Sep 16, 2026 | McNeill Jonathan Officer (President and COO) | Open-market sale | −731 | $17.90 | $13,085 |
| Sep 16, 2026 | Scalzo Richard William Officer (Chief Financial Officer) | Open-market sale | −568 | $17.90 | $10,167 |
| Sep 16, 2026 | Im Ellie Eunkyung Officer (Chief Medical Officer) | Open-market sale | −623 | $17.90 | $11,152 |
| Sep 16, 2026 | Pinkas Jan Officer (Chief Scientific Officer) | Open-market sale | −658 | $17.90 | $11,778 |
| Sep 16, 2026 | Lynch Ryan Officer (See Remarks) | Open-market sale | −240 | $17.90 | $4,296 |
| Jul 16, 2026 | Fairmount Funds Management LLC Director, 10% owner | Open-market purchase | +853,450 | $14.50 | $12,375,025 |
| Jun 22, 2026 | Lynch Ryan Officer (See Remarks) | Open-market sale | −465 | $17.99 | $8,365 |
| Jun 22, 2026 | Pinkas Jan Officer (Chief Scientific Officer) | Open-market sale | −1,288 | $17.99 | $23,171 |
| Jun 22, 2026 | Scalzo Richard William Officer (Chief Financial Officer) | Open-market sale | −1,112 | $17.99 | $20,005 |
| Jun 22, 2026 | Bispham Barbara Harlin Officer (See Remarks) | Open-market sale | −1,218 | $17.99 | $21,912 |
| Jun 22, 2026 | Im Ellie Eunkyung Officer (Chief Medical Officer) | Open-market sale | −1,219 | $17.99 | $21,930 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.